En Carta Diagnostics

€5.0M startup

Announced: Jul 10, 2026
Sector: molecular diagnostics
Investors: 5

Summary

En Carta Diagnostics announced the first closing of €5 million in financing to advance its at-home molecular diagnostics platform. The funding includes equity and non-dilutive financing and will support regulatory certification, industrialisation, and commercial launch of its Lyme disease and STI tests.

Investors

Blue Forest Ventures, Ring Capital, CentraleSupélec Venture, 50 Partners Health, Bpifrance